Objective: To study the quantitative content of serotonin and dopamine in the blood plasma of patients with Parkinson’s disease and to conduct a clinical and laboratory comparison of their concentrations with motor, anxiety-depressive, vegetative and cognitive symptoms of the disease.

Background: Parkinson’s disease (PD) is one of the most common neurodegenerative diseases characterized by progressive loss of dopaminergic neurons. Levodopa is the “gold standard” of therapy, but with prolonged use it causes drug-induced dyskinesia (DI). In recent years, more and more data indicate the role of the serotonergic system in the pathogenesis of DI.

Method: A cohort study was conducted that included patients with Parkinson’s disease of varying duration. Serotonin and dopamine levels in blood plasma were determined using high-performance liquid chromatography (HPLC). Biochemical parameters were correlated with clinical data.

Results: Patients with long-term Parkinson’s disease showed a significant decrease in serotonin levels. A correlation was found between low serotonin levels and the severity of drug-induced dyskinesias, anxiety-depressive and vegetative symptoms.

Conclusion: Serotonergic dysfunction plays an important role in the development of levodopa-induced dyskinesias and associated non-motor manifestations of Parkinson’s disease. Further studies may help in the development of new therapeutic strategies.

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-role-of-serotonergic-mechanisms-in-the-formation-of-levodopa-induced-drug-induced-dyskinesias-in-parkinsons-disease/